For years, parents of children with peanut allergies have lived with constant fear. A tiny amount of peanut hidden in a cookie, sauce, or candy bar could trigger a medical emergency. Researchers have long wondered whether slowly exposing allergic children to peanuts could train the immune system to stop overreacting, but the evidence has often been uncertain or mixed.
Now, a major new study from Sweden suggests that doctors may finally have a safer and more effective way to dramatically reduce peanut allergies in very young children.
Researchers at the Karolinska Institute found that slowly increasing tiny peanut doses over several years allowed most allergic preschool children to tolerate peanuts without dangerous reactions. The results are giving new momentum to a treatment approach known as oral immunotherapy, or OIT.
What Peanut Allergies Really Are
A peanut allergy happens when the immune system mistakenly identifies peanut proteins as dangerous invaders. Instead of ignoring the food, the body launches an aggressive immune response.
Symptoms can range from mild itching to life threatening anaphylaxis. According to the information reviewed in the study, common symptoms include hives, swelling, vomiting, wheezing, breathing difficulty, dizziness, and severe drops in blood pressure. In the worst cases, people can lose consciousness or suffer cardiac arrest.
Peanut allergies are especially feared because they are one of the leading causes of food related anaphylaxis. Even tiny amounts can trigger severe reactions in highly sensitive individuals. Some people can react from cross contamination or even peanut dust in the air.
Unlike milk or egg allergies, peanut allergies also tend to persist. Researchers note that only about 20% to 30% of children naturally outgrow them.
That reality has pushed scientists for decades to search for ways to safely retrain the immune system.
The Idea Behind Slow Up-Dosing
The new research focused on a treatment strategy called oral immunotherapy. The idea is simple in theory but delicate in practice: expose allergic children to extremely small amounts of peanut protein and gradually increase the amount over time.
Researchers have experimented with this concept for years. In fact, the study notes that the first publication involving oral immunotherapy dates all the way back to 1908.
The problem has always been safety.
Previous studies showed that oral immunotherapy could help children become less sensitive to peanuts, but faster dosing schedules often caused frequent allergic reactions, including dangerous anaphylaxis. Some earlier studies reported severe reactions in up to 20% of participants.
That is why the Swedish researchers tried something different. Instead of rapidly increasing doses every two weeks, they used a much slower approach.
“We consider the treatment to be safe if it is carried out under controlled conditions in a healthcare setting,” researcher Caroline Nilsson said.
How the Study Worked
The study, called SMACHO, involved 75 peanut allergic children between 1 and 3 years old in Stockholm, Sweden. Fifty children received oral immunotherapy while 25 avoided peanuts entirely.
Treatment began in the hospital with extremely tiny doses. Researchers started at roughly one quarter of the child’s individual reaction threshold. Very small doses were mixed into flour, while larger doses used peanut puffs called BAMBA.
The children ate peanut doses daily at home, but dose increases only happened every four to six weeks under medical supervision.
Eventually, the children reached a maintenance level of 285 milligrams of peanut protein daily, which is about one and a half peanuts or three peanut puffs.
Researchers continued the treatment for three years.
“This is the first randomized study of oral immunotherapy in toddlers involving a slow up-dosing and a low maintenance dose,” Nilsson said. “We were surprised by how positive the results were.”
The Results Were Dramatic
The outcomes stunned researchers.
After three years of treatment followed by a short peanut free period, 82% of children in the therapy group could tolerate at least 750 milligrams of peanut protein without an allergic reaction. Only 12% of children in the peanut avoidance group could do the same.
Even more impressive, many children tolerated far larger amounts.
Researchers reported that most children could eat up to 25 peanuts after treatment.
Among children who fully completed the protocol, 98% achieved what researchers called “sustained unresponsiveness,” meaning they remained tolerant even after stopping peanut exposure for several weeks.
The study also found that severe reactions became far less common after treatment. Only 2.4% of treated children experienced the most severe reaction category during testing, compared with 25% in the untreated group.
Why Slower May Be Better
One of the most important findings may be that slower treatment appeared safer.
Across more than 43,000 administered peanut doses, adverse reactions occurred after only 0.7% of doses, and most were mild. Common side effects included itchy mouths, mild rashes, or temporary stomach discomfort.
Only a few children required epinephrine injections during treatment, and those events mainly happened during dose escalation.
Researchers believe the slow up-dosing schedule and lower maintenance dose were key reasons for the improved safety profile.
“Our findings indicate that initiating peanut OIT in early childhood, combined with gradual dose escalation and a low maintenance regimen, can minimise adverse events while preserving therapeutic efficacy,” the study concluded.
The slower schedule also made life easier for families. Longer intervals between dose increases gave parents more flexibility for illnesses, travel, and daily life, which researchers say improved compliance and reduced dropouts.
A Major Shift in Confidence
For years, oral immunotherapy has existed in an uncomfortable gray zone. Many doctors saw promise, but concerns about severe reactions made some hesitant to embrace it widely.
The data now strongly suggests that carefully controlled, slow exposure therapy in very young children can substantially reduce peanut allergy severity while keeping risks relatively low.
Still, researchers strongly warn against trying this at home.
“This is not something that parents should attempt at home, as serious reactions can still occur,” researcher Anna Asarnoj said.
The researchers plan to continue monitoring the children long term to see how durable the tolerance remains and how their immune systems continue to change over time.
For families living under the shadow of peanut allergies, the study offers something many have waited years to hear: evidence that the immune system may be trainable after all.
